Core Insights - The technology and manufacturing sectors remain the primary focus for capital investment, with a significant number of financing events reported in the past week [1] - Artificial intelligence, robotics, semiconductors, and advanced manufacturing are highlighted as key areas of interest, with substantial funding rounds indicating strong investor confidence [1][3] - The healthcare sector also saw notable financing activity, reinforcing the dual focus on technology and healthcare as the most promising investment directions [1] Technology and Manufacturing Sector - A total of 36 financing events occurred in the domestic primary market from November 24 to November 30, with 27 disclosing amounts totaling approximately 40.17 billion RMB [1][2] - The artificial intelligence sector completed four financing rounds, raising about 7.6 billion RMB, while the biomedicine sector secured three rounds totaling approximately 3.9 billion RMB [3][4] - Key companies such as Shanghai Wunwen Chip and Jike Technology received significant funding, emphasizing the ongoing attractiveness of hard technology sectors [1][3][43] Healthcare Sector - Jiangsu Zhenyi Medical completed a multi-billion RMB C round financing, while Kaishikadi secured nearly 300 million RMB in B round funding [20][22] - Other companies like Jingwei Vision and Weike Biology also completed financing rounds exceeding 100 million RMB, indicating strong market confidence in innovative medical devices and biopharmaceuticals [1][20][22] Regional Financing Activity - Financing activities were concentrated in Jiangsu, Shanghai, and Beijing, with each region completing nine, nine, and seven financing events respectively [4][5] Active Investment Institutions - Yifeng Capital and BV Baidu Ventures were notably active, each completing two financing rounds primarily in technology and healthcare sectors [5][6]

近日，创新医疗器械研发商精微视达完成超亿元新一轮融资，本轮融资由倚锋灼华基金、华彬沣泰私募基 金、长飞产业基金联合投资。 据悉，本轮融资将主要用于共聚焦显微内镜产品的持续研发、规模化生产、临床应用推广及全球商业化推 进。 2024年7月，精微视达曾完成B轮融资，投资方包括福建泉州、江苏苏州、湖北武汉、福建晋江、江苏无 锡等多地政府基金、产业资本及知名社会资本。 精微视达医疗科技有限公司成立于2014年12月，是一家专注于早期肿瘤精准诊疗的高端医疗器械企业。 历经二十年深耕，通过"产学研医检"深度融合，依托十余项国家重点研发计划支撑，精微视达拿下多张共 聚焦显微内镜注册证，并荣获工信部国家级科学技术成果认证，技术水平国际先进。 文章来源：猎云网 商务合作 商务活动｜宣传推广｜转载开白等 联系电话｜18355423366 END 如果内容对您有所启发，欢迎在评论区留言 请 点赞 、 转发 、 小心心 ，将公众号设置为 星标 点赞 收藏 分享 精微视达全面掌握国产共聚焦显微内镜关键材料、核心元器件到系统整机的关键核心技术，摆脱对进口设 备和技术的依赖，实现了国产共聚焦显微内镜的"自主可控、可复制、可推广"。同时，企 ...

资金将主要用于共聚焦显微内镜产品的持续研发、规模化生产、临床应用推广及全球商业化推进。 11月24日，精微视达医疗科技有限公司（以下简称"精微视达"）宣布完成新一轮融资，本轮融资由倚锋 灼华基金、华彬沣泰私募基金、长飞产业基金联合投资完成，金额超亿元。 ...

Group 1 - The core viewpoint of the article highlights the opportunities for the health consumption sector in China due to the aging population and supportive government policies, as outlined in the "Action Plan for Promoting Healthy Consumption" released by 12 departments including the Ministry of Commerce and the National Health Commission [1] - The discussion at the "European Forum" in Paris emphasized the rapid development of China's medical innovation sector and the unique opportunities for Sino-European cooperation in healthcare, as stated by former French Health Minister Olivier Véran [1][3] - Véran noted that cooperation between China and Europe could lead to both regions becoming long-term partners and global leaders in healthcare, with China needing access to European markets and Europe seeking to deepen connections with Chinese innovation resources [1][3] Group 2 - Olivier Dessajan, CEO of High Life China and President of the French Health Industry Alliance, expressed the importance of collaboration with China, stating that not engaging with China would be a mistake [3] - The establishment of high-end medical service nursing homes in cities like Guangzhou, Hangzhou, and Shenzhen by High Life China reflects the adaptation to local regulations while incorporating French operational mechanisms [3] - The CEO of Pro Pharma, Zhu Fangmeng, emphasized the significance of Sino-European cooperation in innovation and manufacturing, noting that nearly one-third of their overseas market is in Europe [3] Group 3 - The discussion highlighted the advanced technologies available in France and Europe, such as confocal endoscopy and radiofrequency ablation devices, while China leads in AI-assisted treatments and clinical trial results [4] - Véran pointed out the important reforms China has made to facilitate the entry of biopharmaceutical companies into the European market, particularly in modernizing drug regulations and accelerating clinical trials [4] - The strategy for AI application in healthcare should balance caution and innovation to promote harmonious economic relations and public interest between China and Europe, according to Véran [4]